0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Immunologically Produced Lymphopenia

CHIYO CHIBA, MD; MELVYN ROSENBLATT, MS; JIRO YAMANAKA, MD; PAUL L. WOLF, MD; EBERHARD BASSENGE, MD; RICHARD J. BING, MD
Arch Intern Med. 1965;115(5):558-564. doi:10.1001/archinte.1960.03860170040010.
Text Size: A A A
Published online

IN 1899, Metchnikoff 1 first produced a leukocytotoxic serum by injecting spleen and lymph node emulsion from rats and guinea pigs into rabbits. Woodruff,2 Waksman,3 and Hume4 employing rabbit antirat or anti guinea pig lymphocytic serum found that lymphopenia could be produced by in vivo administration of this antiserum. Since the production of lymphopenia by the above method requires daily administration of antiserum, and because of the possibility of anaphylactic reaction, a safer, more practical method for inducing lymphoid system suppression was desired. The early work of Landsteiner 5,6 had shown that coupling autologous peptides and a simple molecule such as glucose to an antigenic protein carrier would cause these substances to elicit antibody formation when injected into the original animals. There is evidence as well,7 that a state of active immunity can be established by coupling autologous neoplastic tissue to an antigenic protein carrier and then reintroducing this complex

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

* * SCHEDULED MAINTENANCE * *

Our websites may be periodically unavailable between midnight and 04:00 ET Thursday, July 10th, for regularly scheduled maintenance.

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 12

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();